BGIM
DGX icon

Boussard & Gavaudan Investment Management’s Quest Diagnostics DGX Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4,164
Closed -$255K – 68
2014
Q3 		$255K Buy
+4,164
New +$257K 0.15% 53

Other funds holding DGX

LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return

Boussard & Gavaudan Investment Management's DGX Position: Q4 2014 in Review

Boussard & Gavaudan Investment Management sold out of Quest Diagnostics (DGX) in Q4 2014, closing a stake of 4,164 shares — an estimated $255K sold.

Boussard & Gavaudan Investment Management first reported a position in DGX in Q3 2014 and held it in 1 quarter. The position peaked at $255K in Q3 2014. 517 funds tracked by Wall St. Rank hold DGX as of Q4 2014.

  • Boussard & Gavaudan Investment Management reported no remaining Quest Diagnostics position as of Q4 2014 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 4,164 Quest Diagnostics shares in Q4 2014, an estimated $255K.
  • Boussard & Gavaudan Investment Management first reported a position in Quest Diagnostics in Q3 2014 and held it in 1 quarter.
  • Boussard & Gavaudan Investment Management's Quest Diagnostics position peaked at $255K in Q3 2014.
  • 517 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2014.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q4 2014, filed 10 Feb 2015.